Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A challenging case of rapidly progressive dementia: cryptococcal meningitis patient with co-existing positive anti-NMDA receptor antibody in CSF
Autoimmune Neurology
P11 - Poster Session 11 (8:00 AM-9:00 AM)
15-005
N/A
Most patients with cryptococcal meningitis (CM) are immunocompromised and have a variable clinical course. We describe a unique case of an immunocompetent patient with CM presenting with rapidly progressive dementia, global aphasia, diffuse rigidity, and concomitant positivity for anti-NMDA receptor antibody in CSF.
N/A

A 58-year-old African American male presented with rapidly progressive dementia over 3-6 months. Upon examination, he was afebrile, tachycardic, nonverbal, and could not follow any commands. Diffuse rigidity with muscle atrophy were observed. He was negative for syphilis, HIV, Hepatitis B or C. MRI of the brain showed hydrocephalus and right cerebellar small diffusion restriction. Electroencephalogram showed mild diffuse slowing.

Lumbar puncture (LP) showed normal opening pressure (8 cm H2O) and lymphocytic leukocytosis (WBC 262 with lymph 70%, RBC 12,000, glucose <20, and protein 1935 mg/dl). Meningitis panel was positive for Cryptococcus and cultures confirmed Cryptococcus neoformans. The patient was initiated on Amphotericin and Flucytosine. In addition, CSF studies also tested positive anti-NDMA receptor antibody with a titer of 1:40 and elevated oligoclonal bands. A repeat LP ten days later revealed similar results to the initial LP including continued positivity for anti-NMDA receptor antibody in CSF. IVIG (2 g/kg over 5 days) was initiated to combat the NMDA receptor encephalitis. CT thorax/abdomen/pelvis was negative for any malignancy. With the above interventions, he had mild improvement in his neurological status and was able to hold simple conversation upon discharge.

To the best of our knowledge, positive NMDA receptor antibodies in patients with CM have not been reported previously. Treatment of CM consists of antifungal therapy and reducing immunosuppressive therapy while treatment of NMDA encephalitis is immunosuppression, which led to a clinical dilemma in our case. Further research should continue to be aimed toward understanding the pathophysiology and treatment of this condition.
Authors/Disclosures
Kyle M. Hodges (UTMB School of Medicine at Galveston)
PRESENTER
No disclosure on file
Diaa Hamouda (Erlanger Baroness Hospital) No disclosure on file
Ruiqing Sun, MD, PhD (UTMB health) Dr. Sun has nothing to disclose.
No disclosure on file